CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Filters
3 research outputs found
Frequency of S492R mutations in the epidermal growth factor receptor: analysis of plasma DNA from patients with metastatic colorectal cancer treated with panitumumab or cetuximab monotherapy
Author
Erbitux® (cetuximab)
Radinsky R
Vectibix® (panitumumab)
Publication venue
'Informa UK Limited'
Publication date
Field of study
No full text
Crossref
A within-trial cost-effectiveness analysis of panitumumab compared with bevacizumab in the first-line treatment of patients with wild-type RAS
Author
Alexandra Christodoulopoulou
Christopher N. Graham
+10 more
Data on file
Data on file.
Gold MR
Guy Hechmati
Hediyyih N. Knox
John H. Strickler
Lorenzo Sabatelli
Shaib W
Tamer Garawin
Vectibix® (panitumumab)
Publication venue
'Informa UK Limited'
Publication date
Field of study
No full text
Crossref
Respuesta de los autores
Author
C Gravalos
C Gómez-Candela
+16 more
Comité de Expertos de la OMS sobre el estado físico: El estado físico: uso e interpretación de la antropometría.
Comité de Expertos de la OMS sobre la obesidad: Obesity: preventingmanaging the global epidemic.
CS Karapetis
D Cunningham
D Gupta
DJ Jonker
ErbituxÒ cetuximab.
European Public Assessment Report for Panitumumab®. London: European Agency for the Evaluation of Medicinal Products EMEA Committee for Propietary Medicinal Products CPMP.
J Rodríguez
KA Foon
LM Weiner
MJ García-Oria
R Arocho
RD Mosteller
RG Amado
Vectibix® panitumumab.
Publication venue
'Springer Science and Business Media LLC'
Publication date
Field of study
No full text
Crossref